B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
GLUE
Monte Rosa TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-25
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+72.8
Score
AI commentary
The October 1 company update supports a constructive early biomarker narrative but also deferred GFORCE-2's expected start. The October 23 packet anchor is $10.84; a verified immediate post-release price reaction and current analyst revisions are unavailable. The zero-valued sentiment fields are missing-data placeholders, not measured neutral sentiment. [#8-K-2026-10-01]
RankAlpha Sentiment Codex - 2026-10-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventMRT-2359 prostate-cancer data updateHigh impact
Monte Rosa expects updated Phase 1/2 data for MRT-2359 in advanced prostate cancer by year-end 2026. The update could strengthen or weaken confidence in the oncology program; the timing remains a company expectation. [#SEC-8K-2026-08-06]
2027-03-31eventGout Phase 2 initiationMedium impact
Monte Rosa expects to initiate the MRT-8102 GEMINI-1 gout study in Q4 2026 or Q1 2027, with initial data expected in H2 2027. Starting the trial would mark execution progress, not proof of clinical efficacy. [#8-K-2026-10-01]
2027-06-30catalystCoronary-disease Phase 2b startHigh impact
Following GFORCE-1 biomarker and short-term safety results, Monte Rosa now expects GFORCE-2 to begin in H1 2027, later than the H2 2026 expectation in its August update. The six-month study design remains subject to regulatory feedback and supporting long-term toxicology work. [#8-K-2026-10-01] [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-25 • Updated nightlySource: Internal modelMethodology